Intrapulmonary shunt and alveolar dead space in a cohort of patients with acute COVID-19 pneumonitis and early recovery

Piotr Harbut¹, G. Kim Prisk², Robert Lindwall¹, Sarah Hamzei¹, Jenny Palmgren¹, Catherine E. Farrow³,⁴,⁵, Goran Hedenstierna⁶,†, Terence C. Amis³,⁴,⁵, Atul Malhotra², Peter D. Wagner² and Kristina Kairaitis³,⁴,⁵

¹Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden. ²Department of Medicine, University of California, San Diego, CA, USA. ³Ludwig Engel Centre for Respiratory Research, Westmead Institute for Medical Research, Sydney, Australia. ⁴Department of Respiratory and Sleep Medicine, Westmead Hospital, Sydney, Australia. ⁵Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. ⁶Department of Medical Sciences, University of Uppsala, Uppsala, Sweden. †Deceased.

Corresponding author: Kristina Kairaitis (kristina.kairaitis@sydney.edu.au)

Shareable abstract (@ERSpublications)
Hypoxaemia in COVID-19 is due to a variable combination of intrapulmonary shunt and increased dead space, likely from both airspace and vascular pathology. Increased dead space present up to 2 months later suggests persistent pulmonary vascular pathology.

Cite this article as: Harbut P, Prisk GK, Lindwall R, et al. Intrapulmonary shunt and alveolar dead space in a cohort of patients with acute COVID-19 pneumonitis and early recovery. Eur Respir J 2023; 61: 2201117 [DOI: 10.1183/13993003.01117-2022].

This single-page version can be shared freely online.

Abstract
Background Pathological evidence suggests that coronavirus disease 2019 (COVID-19) pulmonary infection involves both alveolar damage (causing shunt) and diffuse microvascular thrombus formation (causing alveolar dead space). We propose that measuring respiratory gas exchange enables detection and quantification of these abnormalities. We aimed to measure shunt and alveolar dead space in moderate COVID-19 during acute illness and recovery.

Methods We studied 30 patients (22 males; mean±SD age 49.9±13.5 years) 3–15 days from symptom onset and again during recovery, 55±10 days later (n=17). Arterial blood (breathing ambient air) was collected while exhaled oxygen and carbon dioxide concentrations were measured, yielding alveolar–arterial differences for each gas (\(P_{A-aO2}\) and \(P_{a-ACO2}\), respectively) from which shunt and alveolar dead space were computed.

Results For acute COVID-19 patients, group mean (range) for \(P_{A-aO2}\) was 41.4 (−3.5–69.3) mmHg and for \(P_{a-ACO2}\) was 6.0 (−2.3–13.4) mmHg. Both shunt (% cardiac output) at 10.4% (0–22.0%) and alveolar dead space (% tidal volume) at 14.9% (0–32.3%) were elevated (normal: <5% and <10%, respectively), but not correlated (\(p=0.27\)). At recovery, shunt was 2.4% (0–6.1%) and alveolar dead space was 8.5% (0–22.4%) (both \(p<0.05\) versus acute). Shunt was marginally elevated for two patients; however, five patients (30%) had elevated alveolar dead space.

Conclusions We speculate impaired pulmonary gas exchange in early COVID-19 pneumonitis arises from two concurrent, independent and variable processes (alveolar filling and pulmonary vascular obstruction). For most patients these resolve within weeks; however, high alveolar dead space in ~30% of recovered patients suggests persistent pulmonary vascular pathology.